Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Overview of attention for article published in Frontiers in oncology, September 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 28 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,829 followers.

RT @FrontOncology: New research: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell L…

07 Sep 2021

Reply Repost Favourite

New research: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study: Background Histone deacetylase (HDAC) overexpression has been documented in… https://t.co/O21

07 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.